Practicing Personalized Evidence-Based Medicine in CLL through Risk Stratification and Patient Education
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.
Release Date: January 17, 2017
Expiration Date: January 17, 2018
Expected time to complete this activity as designed: 60 minutes
There are no fees for participating in or receiving credit for this online activity.
The treatment and management of patients with chronic lymphocytic leukemia (CLL) is personalized through risk-stratification based on various factors, such as age, comorbidities, or cytogenetic abnormalities. The multidisciplinary health care provider team, including physicians, pharmacists and nurses, collaborate to appropriately assess for risk factors, devise treatment strategies, select therapy, and manage adverse events. In this activity, participants will learn about key risk-stratification strategies and associated treatment pathways for patients with CLL. Aspects of care that are critical to specific disciplines will also be discussed, such as concomitant medications for pharmacists and patient monitoring for nurses. In addition, participants will gain an understanding of the role of shared decision-making and communication strategies to engage their patients with CLL.
This activity is designed for community oncologists, nurses, and pharmacist members of the interprofessional team who may provide care to patients with CLL.
Upon completion of this educational activity, participants should be able to:
- Describe the current practice guidelines and emerging evidence for the treatment and management of patients with CLL
- Explain the mechanism of action and therapeutic profile of recommended medications and novel therapies
- Determine the appropriate cytogenetic testing strategies and comorbidity assessment tools for patients with CLL, and interpret results to accurately stratify patients and guide therapeutic decisions
- Develop communication strategies and decision aids for the interprofessional health care provider team to educate patients/caregivers on the significance and impact of CLL risk factors, including cytogenetic abnormalities, age and comorbidities, thus supporting shared decision-making to optimize treatment outcomes
Practicing Personalized Evidence-Based Medicine in CLL through Risk Stratification and Patient Education – Beth Faiman, PhD, CNP; Heidi D. Finnes, PharmD, BCOP; Jeffrey Jones, MD
Q & A – Beth Faiman, PhD, CNP; Heidi D. Finnes, PharmD, BCOP; Jeffrey Jones, MD
Instructions for Participation and Credit
This activity is eligible for credit through January 17, 2018. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME and CNE may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.
Beth Faiman, PhD, CNP
Cleveland Clinic Taussig Cancer Institute
Dr. Beth Faiman received her bachelor of science in nursing and registered nurse certification at Ursuline College in Pepper Pike, Ohio. She received a master of science in nursing and certification as an adult nurse practitioner at Kent State University in Kent, Ohio, and a PhD in Clinical Research and Nursing from Case Western Reserve University. Dr. Faiman holds an advanced oncology nurse certification through Oncology Nursing Certification Corporation (ONCC). She is an Adult Nurse Practitioner in the Department of Hematologic Oncology and Blood Disorders at the Cleveland Clinic in Cleveland, Ohio, and adjunct faculty at Ursuline College, Case Western Reserve University and Kent State University.
Dr. Faiman is an active author, presenter, and educator on the topic of multiple myeloma, chronic lymphocytic leukemia, plasma cell dyscrasias, general cancer diagnosis and treatment, as well as management of skeletal and other cancer complications. She is an appointed delegate on the International Myeloma Foundation Nurse Leadership Board. Dr. Faiman is currently editor-in-chief of The Oncology Nurse APN/PA, and is on the editorial board of ASH Clinical News, among others. She has edited several books, authored many chapters, and written numerous articles relating to the diagnosis and treatment of multiple myeloma, treatment adherence, pain, palliation, and cancer symptom management. Dr. Faiman received the 2015 Dean’s Legacy Award for PhD Studies from Case Western Reserve University, and was named the Leukemia and Lymphoma Society’s Woman of the Year for Cleveland and Akron Ohio, 2016.
Heidi D. Finnes, PharmD, BCOP
Pharmacy Cancer Center Research
Mayo Clinic Cancer Center
Dr. Heidi Finnes received her doctor of pharmacy degree from Drake University in Des Moines, Iowa, followed by her Board Certification in Oncology Pharmacy. She is the Manager of Pharmacy Cancer Center Research at the Mayo Clinic Cancer Center (MCCC) in Rochester, Minnesota. She has worked in hematology/oncology for the last sixteen years, seven years as an inpatient hematology/oncology pharmacist, and nine years in the outpatient cancer center.
Dr. Finnes holds membership in the Eastern Cooperative Oncology Group (ECOG) Pharmacy, Genitourinary and Melanoma committees. She is the current chair of the Alliance for Clinical Trials in Oncology Pharmacy Committee, and is active on the Alliance Neuro-Oncology and Experimental Therapeutics Committees. In addition, she is active in the Hematology Oncology Pharmacists Association (HOPA) and was recently elected as a board member at-large. Dr. Finnes is also a member of the MCCC Scientific Research Committees A and B, Melanoma, GI and Phase I Operations Group where she provides input on clinical trials during protocol development, authors drug templates, and offers recommendations for supportive care. She also sets up the computerized physician order sets via Web/CDM (clinical data management), and completes electronic and face-to-face pharmacy consultations on hematology/oncology patients to review drug interactions in patients initiating therapy per a clinical trial.
Jeffrey Jones, MD
Clinical Research Director
Division of Hematology
The Ohio State University
Dr. Jeffrey Jones received his medical degree from the University of Michigan Medical School. He completed internal medicine residency training at McGill University in Montreal, Quebec, and subsequent fellowship training in hematology and medical oncology at MD Anderson Cancer Center in Houston, Texas. Dr. Jones is Associate Professor of Internal Medicine and Clinical Research Director in the Division of Hematology, and Disease Specific Research Group Leader for Chronic Lymphocytic Leukemia and Hairy Cell Leukemia at The Ohio State University Comprehensive Cancer Center in Columbus, Ohio.
Dr. Jones’s research focuses on novel therapies for the treatment of CLL and related lymphoid malignancies. He has chaired several multicenter clinical trials of novel agents, including therapeutic antibodies and small molecule inhibitors of B-cell receptor signaling and BCL2, with the potential to improve efficacy while limiting treatment-related toxicities. He has co-authored more than 75 papers in the peer-reviewed literature, and he lectures frequently both nationally and internationally.
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-17-134-H01-P. Knowledge-based CPE activity.
In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the login/registration on the home page of this site.
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 17-134-049
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.
Dr. Beth Faiman has received honoraria related to speakers’ bureau activities and as a consultant from Amgen Inc., Bristol-Myers Squibb Company, Celgene Corporation, and Takeda Oncology.
Dr. Heidi Finnes has disclosed no relevant financial relationships.
Dr. Jeffrey Jones has received honoraria related to formal advisory activities and grant support related to research activities from AbbVie Inc., Genentech, Inc., Gilead, Janssen Pharmaceuticals, Inc., and Pharmacyclics, Inc.
Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, and Patrick Brooks, PharmD, Medical Director, Oncology, have no relevant financial relationships.
Peer Reviewer Disclosure
In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.
Physician Payments, Sunshine Act
MediCom Worldwide, Inc. complies with the Physician Payments Sunshine Act as part of the Affordable Care Act (ACA). Accordingly, we may be required to collect information on transfer of value provided to any covered recipient under the ACA.
MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.
If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at firstname.lastname@example.org.
Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Genentech
©2017 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.
You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.